- Home
- GRI vs PALI Comparison
GRI vs PALI Comparison
Compare GRI & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- PALI
- Stock Information
- Founded
- GRI 2018
- PALI 1996
- Country
- GRI United States
- PALI United States
- Employees
- GRI N/A
- PALI 8
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRI Health Care
- PALI Health Care
- Exchange
- GRI Nasdaq
- PALI Nasdaq
- Market Cap
- GRI 3.2M
- PALI 3.8M
- IPO Year
- GRI N/A
- PALI N/A
- Fundamental
- Price
- GRI $1.38
- PALI $0.70
- Analyst Decision
- GRI Strong Buy
- PALI Strong Buy
- Analyst Count
- GRI 2
- PALI 2
- Target Price
- GRI $22.00
- PALI $12.00
- AVG Volume (30 Days)
- GRI 358.1K
- PALI 410.9K
- Earning Date
- GRI 05-15-2025
- PALI 05-12-2025
- Dividend Yield
- GRI N/A
- PALI N/A
- EPS Growth
- GRI N/A
- PALI N/A
- EPS
- GRI N/A
- PALI N/A
- Revenue
- GRI N/A
- PALI N/A
- Revenue This Year
- GRI N/A
- PALI N/A
- Revenue Next Year
- GRI N/A
- PALI N/A
- P/E Ratio
- GRI N/A
- PALI N/A
- Revenue Growth
- GRI N/A
- PALI N/A
- 52 Week Low
- GRI $1.10
- PALI $0.60
- 52 Week High
- GRI $66.30
- PALI $5.15
- Technical
- Relative Strength Index (RSI)
- GRI 39.90
- PALI 44.12
- Support Level
- GRI $1.24
- PALI $0.67
- Resistance Level
- GRI $1.49
- PALI $0.86
- Average True Range (ATR)
- GRI 0.12
- PALI 0.06
- MACD
- GRI 0.07
- PALI -0.01
- Stochastic Oscillator
- GRI 59.52
- PALI 22.24
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.